Last reviewed · How we verify
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive dysfunction in Psychotic Spectrum Disorder.
Details
| Lead sponsor | NYU Langone Health |
|---|---|
| Status | COMPLETED |
| Enrolment | 139 |
| Start date | Tue Jul 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Schizophrenia
- Bipolar Disorder
Interventions
- Cognitive Function Assessments
Countries
United States